Ketan Desai - Comments
CEO of International Medical Consultants, IMC Radiology, and CMO of Levolta Pharma

Ketan Desai, MD, PhD, is the Founder and Chief Executive Officer of IMC Radiology, the founder and Chief Medical Officer of LeVolta Pharma, Founder and CEO of UBDoc (an artificial intelligence based company for health care) and a part-time practicing physician. One of his inventions was acquired ... more

Latest Comments
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 month ago

Written by Cytodyn insiders!! What conflict of interest!! Zero credibilty!! LOL!!!!

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 month ago

What an ignorant and biased rant. Look at these reviews on the status of immune response to COVID19. These are by independent scientists who, unlike you or Cytodyn, have no conflict of interest. They are peer reviewed and are in world class journals Sciene, Lancet. CCR5 is not a pathway that anyone of repute espouses.

www.sciencedirect.com/.../S1074761320301837

science.sciencemag.org/content/369/6508/eabc8511

www.thelancet.com/.../fulltext#seccestitle60

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 month ago

What a poor response. You DID NOT SHOW A SINGLE PEER REVIEWED INDEPENDENT ARTICLE ON CCR5 AND COVID19. We are not talking about HIV but COVID19. Stay on topic, will you, and stop dissembling the truth?

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 month ago

Scientific knowledge that Cytodyn pumpers dont know or deliberately obfuscate - neutrophils in COVID19 are determined by CCR8, and not CCR5. See article below. Leronlimab binds CCR5, not CCR8. Which is why other than Cytodyn, NOBODY IN THE SCIENTIFIC OR PHARMA COMMUNITY trusts cytodyn data.

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 month ago

Then don't respond. You must have a guilty conscience.

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 month ago

Which is why you should do your own due diligence and not listen to pumpers.

In this article: CYDY
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
1 month ago

Not everyone against CYDY is a short. Some like me dislike lies and respond to restore clarity and science.

1. The drug works. In HIV, yes. In COVID19, no. It MISSED THE PRIMARY ENDPOINT

2. NASDAQ uplisting in process. Unlikely. IS NOT MEETING CRITERIA.

3. MHRA is positive on funding trials for EAMS patients in the U.K. MORE GOEBBLES DOUBLESPEAK.

4. NASH trial to start soon. That is a problem as the company is running out of money, and has no expertise in NASH. Most importantly, SCIENCE DOES NOT SUPPORT NASH.

5. Long Hauler Study to start soon. SEE 1 ABOVE. WON'T WORK.

6 At least 4 journal articles submitted for publication. YET NOTHING PUBLISHED.

7. Leronlimab crosses the blood-brain barrier. SO WHAT? NO SCIENCE TO SUPPORT ANY CNS INDICATION.

8. GILD bought a comparable drug platform with an inferior safety profile for $21 billion. BUT IMMUNOMEDICS DRUG WORKS, LMAB IS NOT AS GOOD. IF LMAB IS SO GOOD, WHY HAS NO PHARMA COMPANY APPROACHED IT? NO VC?

9. MANAGEMENT HAS NO DRUG DEVELOPMENT EXPERIENCE. ONLY EXPERIENCE IN BEATING WIVES AND SELLING FAKE INDIAN ARTIFACTS.

In this article: CYDY
CytoDyn’s Data: Approvable Drug Sets Stage For Near-Term Move Upward
2 months ago

In my view, presenting only one, positive, aspect of a company, or cherry picking data, while ignoring the negatives, is tantamount to being deceitful. A balanced article should present both the negatives and the positives.

In this article: CYDY
CytoDyn’s Data: Approvable Drug Sets Stage For Near-Term Move Upward
2 months ago

Very slim. One has to do ones own due diligence. Saying that since someone lent them 20 million, it must be good is very foolish. And the company CEO is a felon who was convicted of wife beating as well as selling fake Indian artifacts. And they release data (or not release data, to be precise, very selectively). So, yes, they are liars.

Since the trial missed its primary endpoint in phase II, the FDA will ask them to conduct at least one phase III study (with 90%) power. Which means more patients, longer timelines, and more money (which the prodigal (wasteful) company does not have much of (see 10K released last week). If they could not meet endpoints in Mild/Moderate patients, chances of meeting it in the Phase II/III severe patients is even less likely as the patients are much sicker.

In this article: CYDY
1 to 10 of 19 comments
1 2